AR022017A1 - Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica - Google Patents

Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica

Info

Publication number
AR022017A1
AR022017A1 ARP990106748A ARP990106748A AR022017A1 AR 022017 A1 AR022017 A1 AR 022017A1 AR P990106748 A ARP990106748 A AR P990106748A AR P990106748 A ARP990106748 A AR P990106748A AR 022017 A1 AR022017 A1 AR 022017A1
Authority
AR
Argentina
Prior art keywords
agent
treatment
disorder
treat
production
Prior art date
Application number
ARP990106748A
Other languages
English (en)
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR022017A1 publication Critical patent/AR022017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revela un agente para el tratamiento del trastorno de la funcion de las células visuales que contiene un inhibidor de interleucina 2 tal como uncompuesto macrolido, particularmente FK506. Se describe además, el uso de dicho inhibidor para la preparacion de composiciones farmacéuticas.
ARP990106748A 1998-12-24 1999-12-23 Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica AR022017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11393998P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
AR022017A1 true AR022017A1 (es) 2002-09-04

Family

ID=22352417

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106748A AR022017A1 (es) 1998-12-24 1999-12-23 Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica

Country Status (13)

Country Link
EP (1) EP1140134A1 (es)
JP (1) JP2002542150A (es)
KR (1) KR20010099928A (es)
CN (1) CN1224420C (es)
AR (1) AR022017A1 (es)
AU (1) AU781049B2 (es)
BR (1) BR9917113A (es)
CA (1) CA2356382A1 (es)
MX (1) MXPA01006449A (es)
NO (1) NO20013146L (es)
NZ (1) NZ513111A (es)
TW (1) TW546145B (es)
WO (1) WO2000038703A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
WO2003061519A2 (en) 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
AU2003272471B2 (en) 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US20210338770A1 (en) * 2018-10-15 2021-11-04 Osaka University Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003049A1 (en) * 1990-08-23 1992-03-05 New York University Methods and compositions for treating t-cell mediated diseases
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
JP2002511868A (ja) * 1997-06-30 2002-04-16 アラーガン・セイルズ・インコーポレイテッド 増殖性硝子体網膜症を治療するためのカルシウム遮断薬
CZ287497B6 (cs) * 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders

Also Published As

Publication number Publication date
AU1690600A (en) 2000-07-31
NO20013146L (no) 2001-08-20
NZ513111A (en) 2003-10-31
WO2000038703A1 (en) 2000-07-06
TW546145B (en) 2003-08-11
JP2002542150A (ja) 2002-12-10
EP1140134A1 (en) 2001-10-10
AU781049B2 (en) 2005-05-05
KR20010099928A (ko) 2001-11-09
NO20013146D0 (no) 2001-06-22
CN1224420C (zh) 2005-10-26
CA2356382A1 (en) 2000-07-06
BR9917113A (pt) 2001-10-23
MXPA01006449A (es) 2002-04-24
CN1352565A (zh) 2002-06-05

Similar Documents

Publication Publication Date Title
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR009457A1 (es) Inhibidores de metaloproteasa heterociclica y uso de la misma para preparar composiciones farmaceuticas.
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
CO5160320A1 (es) Metodos y composiciones para la prevencion de tolerancia a medicamentos das.
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
RS49981B (sr) Upotreba derivata hidroksilamina za dobijanje farmaceutskih kompozicija korisnih za povećanje ekspresije i aktivnosti molekulskih šaperona
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
BR0312427A (pt) Combinação, uso de uma combinação, método para a produção de um efeito inibitório de ibat em um animal de sangue quente, método de prevenção de diarréia, composição farmacêutica, método de tratamento de condições hiperlipidêmicas em um animal de sangue quente, e, uso de um sal metálico
AU7023987A (en) Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
AR022358A1 (es) Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
DE69919597D1 (de) Topische formulierungen, die hautpenetrations-mittel enthalten, und ihre verwendung
CO5050343A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
AR028987A1 (es) Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
AR010432A1 (es) Composiciones farmaceuticas que contienen acido ricinoleico y su uso para la terapia antiinflamatoria y analgesica
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal